[1]
|
Zutshi D, Cloud LJ, Factor SA. Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic[J]. Tremor Other Hyperkinet Mov(N Y), 2014, 4: 266. doi: 10.5334/tohm.199 |
[2]
|
Carbon M, Hsieh CH, Kane JM, et al. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis[J]. J Clin Psychiatry, 2017, 78: e264-e278. doi: 10.4088/JCP.16r10832 |
[3]
|
Schonecker M. Paroxysmal dyskinesia as the effect of megaphen[J]. Nervenarzt, 1957, 28: 550-553. https://www.ncbi.nlm.nih.gov/pubmed/12583484 |
[4]
|
Vinuela A, Kang UJ. Reversibility of tardive dyskinesia syndrome[J]. Tremor Other Hyperkinet Mov (N Y), 2014, 4: 282. doi: 10.5334/tohm.217 |
[5]
|
Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications[J]. J Clin Psychiatry, 1993, 54: 133-139. |
[6]
|
Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients[J]. Arch Gen Psychiatry, 1995, 52: 756-765. doi: 10.1001/archpsyc.1995.03950210050010 |
[7]
|
Patel RS, Mansuri Z, Chopra A. Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study[J]. Heliyon, 2019, 5: e01745. doi: 10.1016/j.heliyon.2019.e01745 |
[8]
|
Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis[J]. BMC Neurol, 2019, 19: 174. doi: 10.1186/s12883-019-1385-4 |
[9]
|
Saklad SR. Identifying Tardive Dyskinesia: Risk Factors, Functional Impact, and Diagnostic Tools[J]. J Clin Psychiatry, 2020, 81: TV18059BR1C. |
[10]
|
Uludag K, Wang DM, Goodman C, et al. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia[J]. Asian J Psychiatr, 2021, 66: 102877. doi: 10.1016/j.ajp.2021.102877 |
[11]
|
van Harten PN, Tenback DE. Tardive dyskinesia: clinical presentation and treatment[J]. Int Rev Neurobiol, 2011, 98: 187-210. https://www.sciencedirect.com/science/article/pii/B9780123813282000080 |
[12]
|
Meltzer HY. Update on typical and atypical antipsychotic drugs[J]. Annu Rev Med, 2013, 64: 393-406. doi: 10.1146/annurev-med-050911-161504 |
[13]
|
Blanchet PJ. A Focused Update on Tardive Dyskinesia[J]. Can J Neurol Sci, 2020, 47: 747-755. doi: 10.1017/cjn.2020.131 |
[14]
|
Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia[J]. Aliment Pharmacol Ther, 2010, 31: 11-9. doi: 10.1111/j.1365-2036.2009.04189.x |
[15]
|
Alford EL, Wheless JW, Phelps SJ. Treatment of Genera-lized Convulsive Status Epilepticus in Pediatric Patients[J]. J Pediatr Pharmacol Ther, 2015, 20: 260-289. doi: 10.1385/1-59259-945-1:265 |
[16]
|
Cornett EM, Novitch M, Kaye AD, et al. Medication-Induced Tardive Dyskinesia: A Review and Update[J]. Ochsner J, 2017, 17: 162-174. https://www.ncbi.nlm.nih.gov/pubmed/6106395 |
[17]
|
Caroff SN. Recent Advances in the Pharmacology of Tardive Dyskinesia[J]. Clin Psychopharmacol Neurosci, 2020, 18: 493-506. doi: 10.9758/cpn.2020.18.4.493 |
[18]
|
Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis[J]. Mov Disord, 2012, 27: 1205-1215. |
[19]
|
Seeman P, Tinazzi M. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2013, 44: 178-183. doi: 10.1016/j.pnpbp.2013.02.011 |
[20]
|
Frei K. Tardive dyskinesia: Who gets it and why[J]. Parkinsonism Relat Disord, 2019, 59: 151-154. doi: 10.1016/j.parkreldis.2018.11.017 |
[21]
|
Zai CC, Maes MS, Tiwari AK, et al. Genetics of tardive dyskinesia: Promising leads and ways forward[J]. J Neurol Sci, 2018, 389: 28-34. doi: 10.1016/j.jns.2018.02.011 |
[22]
|
Koola MM, Tsapakis EM, Wright P, et al. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?[J]. J Psychopharmacol, 2014, 28: 665-670. doi: 10.1177/0269881114523861 |
[23]
|
Lu JY, Tiwari AK, Freeman N, et al. Liver enzyme CYP2D6 gene and tardive dyskinesia[J]. Pharmacogenomics, 2020, 21: 1065-1072. doi: 10.2217/pgs-2020-0065 |
[24]
|
Vaiman EE, Shnayder NA, Novitsky MA, et al. Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients[J]. Biomedicines, 2021, 9: 879 doi: 10.3390/biomedicines9080879 |
[25]
|
Tsai HT, Caroff SN, Miller DD, et al. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial[J]. Am J Med Genet B Neuropsychiatr Genet, 2010, 153B: 336-340. https://pubmed.ncbi.nlm.nih.gov/19475583/ |
[26]
|
Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia[J]. J Psychiatr Res, 2013, 47: 1760-1765. doi: 10.1016/j.jpsychires.2013.07.025 |
[27]
|
Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility[J]. Psychopharmacology(Berl), 2000, 152: 408-413. doi: 10.1007/s002130000521 |
[28]
|
Syu A, Ishiguro H, Inada T, et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia[J]. Neuropsychopharmacology, 2010, 35: 1155-1164. doi: 10.1038/npp.2009.220 |
[29]
|
Greenbaum L, Alkelai A, Zozulinsky P, et al. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations[J]. Pharmacogenomics J, 2012, 12: 513-520. doi: 10.1038/tpj.2011.32 |
[30]
|
Zai CC, Lee FH, Tiwari AK, et al. Investigation of the HSPG2 Gene in Tardive Dyskinesia-New Data and Meta-Analysis[J]. Front Pharmacol, 2018, 9: 974. doi: 10.3389/fphar.2018.00974 |
[31]
|
Arinami T, Inada T. Genome-wide association analyses for neuroleptic-induced tardive dyskinesia[J]. Nihon Shinkei Seishin Yakurigaku Zasshi, 2011, 31: 155-162. |
[32]
|
Aberg K, Adkins DE, Bukszár J, et al. Genomewide association study of movement-related adverse antipsychotic effects[J]. Biol Psychiatry, 2010, 67: 279-282. doi: 10.1016/j.biopsych.2009.08.036 |
[33]
|
Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia[J]. Pharmacogenet Genomics, 2008, 18: 317-323. doi: 10.1097/FPC.0b013e3282f70492 |
[34]
|
Levchenko A, Kanapin A, Samsonova A, et al. A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2021, 105: 110134. doi: 10.1016/j.pnpbp.2020.110134 |
[35]
|
Ayhan F, Konopka G. Regulatory genes and pathways disrupted in autism spectrum disorders[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2019, 89: 57-64. https://www.sciencedirect.com/science/article/pii/S0278584618304615 |
[36]
|
Li W, Pozzo-Miller L. Dysfunction of the corticostriatal pathway in autism spectrum disorders[J]. J Neurosci Res, 2020, 98: 2130-2147. doi: 10.1002/jnr.24560 |
[37]
|
Lam M, Chen CY, Li Z, et al. Comparative genetic architectures of schizophrenia in East Asian and European populations[J]. Nat Genet, 2019, 51: 1670-1678. https://www.biorxiv.org/content/biorxiv/early/2018/10/18/445874.full.pdf |
[38]
|
Lam M, Hill WD, Trampush JW, et al. Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways[J]. Am J Hum Genet, 2019, 105: 334-350. https://www.academia.edu/en/58176685/Pleiotropic_Meta_Analysis_of_Cognition_Education_and_Schizophrenia_Differentiates_Roles_of_Early_Neurodevelopmental_and_Adult_Synaptic_Pathways |
[39]
|
Sollis E, Graham SA, Vino A, et al. Identification and functional characterization of de novo FOXP1 variants provides novel insights into the etiology of neurodevelopmental disorder[J]. Hum Mol Genet, 2016, 25: 546-557. https://academic.oup.com/hmg/article/25/3/546/2384672 |
[40]
|
Lim K, Lam M, Zai C, et al. Genome wide study of tardive dyskinesia in schizophrenia[J]. Transl Psychiatry, 2021, 11: 351. |
[41]
|
Caroff SN, Leong SH, Roberts CB, et al. Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia[J]. J Clin Psychopharmacol, 2020, 40: 373-380. |
[42]
|
Jain R, Correll CU. Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis[J]. J Clin Psychiatry, 2018, 79: nu17034ah1c. https://ohsu.pure.elsevier.com/en/publications/the-differential-diagnosis-of-tardive-dyskinesia-2 |
[43]
|
Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia[J]. J Neurol Sci, 2018, 389: 21-27. https://www.sciencedirect.com/science/article/pii/S0022510X18300704 |
[44]
|
Erbe S. Prevention and Treatment of Antipsychotic-induced Tardive Dyskinesia[J]. Fortschr Neurol Psychiatr, 2019, 87: 217-224. |
[45]
|
Caroff SN, Citrome L, Meyer J, et al. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia[J]. J Clin Psychiatry, 2020, 81: 19cs12983. |
[46]
|
Khorassani F, Luther K, Talreja O. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia[J]. Am J Health Syst Pharm, 2020, 77: 167-174. |
[47]
|
Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment Recommendations for Tardive Dyskinesia[J]. Can J Psychiatry, 2019, 64: 388-399. https://europepmc.org/article/pmc/6591749 |
[48]
|
Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia[J]. Am J Psychiatry, 2020, 177: 868-872. |
[49]
|
Margolius A, Fernandez HH. Current treatment of tardive dyskinesia[J]. Parkinsonism Relat Disord, 2019, 59: 155-160. https://www.sciencedirect.com/science/article/pii/S135380201830556X |
[50]
|
Arya D, Khan T, Margolius AJ, et al. Tardive Dyskinesia: Treatment Update[J]. Curr Neurol Neurosci Rep, 2019, 19: 69. https://www.ncbi.nlm.nih.gov/pubmed/6106395 |
[51]
|
Lindenmayer JP, Verghese C, Marder SR, et al. A long-term, open-label study of valbenazine for tardive dyskinesia[J]. CNS Spectr, 2021, 26: 345-353. |
[52]
|
Debrey SM, Goldsmith DR. Tardive Dyskinesia: Spotlight on Current Approaches to Treatment[J]. Focus (Am Psychiatr Publ), 2021, 19: 14-23. |
[53]
|
Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy[J]. Am J Psychiatry, 1990, 147: 445-451. https://www.ncbi.nlm.nih.gov/pubmed/6241738 |
[54]
|
Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia[J]. J Clin Psychopharmacol, 1997, 17: 88-91. |
[55]
|
Pappa S, Tsouli S, Apostolou G, et al. Effects of amantad-ine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study[J]. Clin Neuropharmacol, 2010, 33: 271-275. |
[56]
|
Zhang WF, Tan YL, Zhang XY, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial[J]. J Clin Psychiatry, 2011, 72: 615-621. |
[57]
|
Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia[J]. Neurology, 2016, 86: 651-659. https://www.ncbi.nlm.nih.gov/pubmed/26791148 |
[58]
|
Gruber D, Südmeyer M, Deuschl G, et al. Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial[J]. Brain Stimul, 2018, 11: 1368-1377. https://www.sciencedirect.com/science/article/pii/S1935861X18302894 |
[59]
|
Factor SA. Management of Tardive Syndrome: Medications and Surgical Treatments[J]. Neurotherapeutics, 2020, 17: 1694-1712. |
[60]
|
Chen CY, Chiang HL, Fuh JL. Tardive syndrome: An update and mini-review from the perspective of phenomeno-logy[J]. J Chin Med Assoc, 2020, 83: 1059-1065. |